: Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China


Shares of Casi Pharmaceuticals Inc. CASI, +0.50% were up 10% in premarket trading on Friday after the company said China will allow a Phase 1 clinical trial evaluating a multiple myeloma drug developed by the privately held Cleave Therapeutics. The study is expected to start this year. Casi has a subsidiary in Beijing that supports its focus on acquiring and commercializing therapies for the Chinese market. The company’s stock is down 73.9% over the past 12 months, while the broader S&P 500 SPX, +2.28% has declined 19.0%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Employers in these two states now post salary ranges for job listings. Millions of workers will now have more pay transparency.
Next articleTaxWatch: Is driving a big part of your business? Good news: IRS increases tax-deductible mileage rate. Here’s how much you can deduct.


Please enter your comment!
Please enter your name here